The CDC reports that, in the United States, the respiratory syncytial virus (RSV) vaccine Arexvy has been administered in error to some children and pregnant people. Arexvy is not approved for use in infants or young children, or pregnant people. Most of the reported administration errors occurred in outpatient settings (e.g. GP clinics and pharmacies).
In January Arexvy was registered by the Therapeutic Goods Administration (TGA) for use in Australia, for the immunisation of people aged 60 years and older to prevent lower respiratory tract disease caused by RSV.
ATAGI (Australian Technical Advisory Group on Immunisation) today (29 February 2024) published guidance on the clinical use of Arexvy.